Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 – 2012)

Bibliography

• Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-74
   PubMed Web of Science ®Google Scholar
• Rafice SA, Chauhan N, Efimov I, et al. Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase. Biochem Soc Trans 2009;37:408-12
   PubMed Web of Science ®Google Scholar
• Sono M, Roach MP, Coulter ED, Dawson JH. Heme-containing oxygenases. Chem Rev 1996;96:2841-88
   PubMed Web of Science ®Google Scholar
• Hwu P, Du MX, Lapointe R, et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000;164:3596-9
   PubMed Web of Science ®Google Scholar
• Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 2012;72:5435-40
   PubMed Web of Science ®Google Scholar
• Kudo Y, Boyd CA. Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection. Biochim Biophys Acta 2000;1500:119-24
   PubMed Web of Science ®Google Scholar
• Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281:1191-3
   PubMed Web of Science ®Google Scholar
• Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006;12:1144-51
   PubMed Web of Science ®Google Scholar
• Okamoto A, Nikaido T, Ochiai K, et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005;11:6030-9
   PubMed Web of Science ®Google Scholar
• Leung BS, Stout LE, Shaskan EG, Thompson RM. Differential induction of indoleamine-2,3-dioxygenase (IDO) by interferon-gamma in human gynecologic cancer cells. Cancer Lett 1992;66:77-81
   PubMed Web of Science ®Google Scholar
• Muller AJ, DuHadaway JB, Donover PS, et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312-19
   PubMed Web of Science ®Google Scholar
• Muller AJ, Malachowski WP, Prendergast GC. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets 2005;9:831-49
   PubMed Web of Science ®Google Scholar
• Muller AJ, Prendergast GC. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res 2005;65:8065-8
   PubMed Web of Science ®Google Scholar
• Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007;7:31-40
   PubMed Web of Science ®Google Scholar
• Di Pucchio T, Danese S, De Cristofaro R, Rutella S. Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds. Expert Opin Ther Patents 2010;20:229-50
   PubMed Web of Science ®Google Scholar
• Prendergast GC, Chang MY, Mandik-Nayak L, et al. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem 2011;18:2257-62
   PubMed Web of Science ®Google Scholar
• Xu H, Oriss TB, Fei M, et al. Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc Natl Acad Sci USA 2008;105:6690-5
   PubMed Web of Science ®Google Scholar
• Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003;24:242-8
   PubMed Web of Science ®Google Scholar
• Kiank C, Zeden JP, Drude S, et al. Psychological stress-induced, IDO1-dependent tryptophan catabolism: implications on immunosuppression in mice and humans. PLoS ONE 2010;5:e11825
   PubMed Web of Science ®Google Scholar
• Ravishankar B, Liu H, Shinde R, et al. Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc Natl Acad Sci USA 2012;109:3909-14
   PubMed Web of Science ®Google Scholar
• Favre D, Mold J, Hunt PW, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010;2:32ra36
   PubMed Web of Science ®Google Scholar
• Fuchs D, Forsman A, Hagberg L, et al. Immune activation and decreased tryptophan in patients with HIV-1 infection. J Interferon Res 1990;10:599-603
   PubMedGoogle Scholar
• Potula R, Poluektova L, Knipe B, et al. Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 2005;106:2382-90
   PubMed Web of Science ®Google Scholar
• Pallotta MT, Orabona C, Volpi C, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 2011;12:870-8
   PubMed Web of Science ®Google Scholar
• Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011;478:197-203
   PubMed Web of Science ®Google Scholar
• Pilotte L, Larrieu P, Stroobant V, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci USA 2012;109(7):2497-502
   PubMed Web of Science ®Google Scholar
• Madge DG, Hazelwood RI, Jones HT, Salter M. Novel tryptophan dioxygenase inhibitors and combined tryptophan dioxygenase/5-HT reuptake inhibitors. Bioorg Med Chem Lett 1996;6:857-60
   Web of Science ®Google Scholar
• Dolusic E, Larrieu P, Moineaux L, et al. Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. J Med Chem 2011;54:5320-34
   PubMed Web of Science ®Google Scholar
• Macchiarulo A, Camaioni E, Nuti R, Pellicciari R. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease. Amino Acids 2009;37:219-29
   PubMed Web of Science ®Google Scholar
• Cady SG, Sono M. 1-methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 1991;291:326-33
   PubMed Web of Science ®Google Scholar
• Eguchi N, Watanabe Y, Kawanishi K, et al. Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives. Arch Biochem Biophys 1984;232:602-9
   PubMed Web of Science ®Google Scholar
• Dolusic E, Larrieu P, Blanc S, et al. Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors. Bioorg Med Chem 2011;19:1550-61
   PubMed Web of Science ®Google Scholar
• Dolušić E, Larrieu P, Blanc S, et al. Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors. Eur J Med Chem 2011;46:3058-65
   PubMed Web of Science ®Google Scholar
• Brastianos HC, Vottero E, Patrick BO, et al. Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua. J Am Chem Soc 2006;128:16046-7
   PubMed Web of Science ®Google Scholar
• Pereira A, Vottero E, Roberge M, et al. Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod 2006;69:1496-9
   PubMed Web of Science ®Google Scholar
• Banerjee T, Duhadaway JB, Gaspari P, et al. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 2008;27:2851-7
   PubMed Web of Science ®Google Scholar
• Gaspari P, Banerjee T, Malachowski WP, et al. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem 2006;49:684-92
   PubMed Web of Science ®Google Scholar
• Carr G, Chung MK, Mauk AG, Andersen RJ. Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A. J Med Chem 2008;51:2634-7
   PubMed Web of Science ®Google Scholar
• Kumar S, Malachowski WP, DuHadaway JB, et al. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem 2008;51:1706-18
   PubMed Web of Science ®Google Scholar
• Dolusic E, Larrieu P, Meinguet C, et al. Indoleamine 2,3-dioxygenase inhibitory activity of derivatives of marine alkaloid tsitsikammamine A. Bioorg Med Chem Lett 2013;23:47-54
   PubMed Web of Science ®Google Scholar
• Sono M, Cady SG. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands. Biochemistry 1989;28:5392-9
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Oda S, Otsuki T, et al. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci USA 2006;103:2611-16
   PubMed Web of Science ®Google Scholar
• Yue EW, Douty B, Wayland B, et al. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J Med Chem 2009;52:7364-7
   PubMed Web of Science ®Google Scholar
• Incyte Corp. N-Hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase. WO2007075598; 2007
   Google Scholar
• Incyte Corp. N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase. WO2008058178; 2008
   Google Scholar
• Incyte Corp. 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase. WO2010005958; 2010
   Google Scholar
• Incyte Corp. N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase. WO2007095050; 2007
   Google Scholar
• Newlink Genetics. Ido inhibitors. WO2009073620; 2009
   Google Scholar
• Newlink Genetics. Ido inhibitors. WO2009132238; 2009
   Google Scholar
• Kumar S, Jaller D, Patel B, et al. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem 2008;51:4968-77
   PubMed Web of Science ®Google Scholar
• Newlink Genetics. Imidazole derivatives as ido inhibitors. WO2011056652; 2011
   Google Scholar
• Ludwig Institute For Cancer Research Ltd. Ido inhibitors and therapeutic uses thereof. WO2009127669; 2009
   Google Scholar
• Rohrig UF, Awad L, Grosdidier A, et al. Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem 2010;53:1172-89
   PubMed Web of Science ®Google Scholar
• Ludwig Institute For Cancer Research Ltd. Hydroxyanthranilic acid or salts thereof for treating cancer or infections. WO2009063241; 2009
   Google Scholar
• Lankenau Institute For Medical Research. Novel ido inhibitors and methods of use thereof. WO2008115804; 2008
   Google Scholar
• The University Of British Columbia. Substituted quinone indoleamine 2,3-dioxygenase (ido) inhibitors and syntheses and uses therefor. WO2008052352; 2008
   Google Scholar
• The University Of British Columbia. Indoleamine 2,3-Dioxygenase (IDO) Inhibitors. US20090042868; 2009
   Google Scholar
• Vottero E, Balgi A, Woods K, et al. Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast. Biotechnol J 2006;1:282-8
   PubMedGoogle Scholar
• Lob S, Konigsrainer A, Schafer R, et al. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2008;111:2152-4
   PubMed Web of Science ®Google Scholar
• Qian F, Villella J, Wallace PK, et al. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res 2009;69:5498-504
   PubMed Web of Science ®Google Scholar
• Lob S, Konigsrainer A, Zieker D, et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 2009;58:153-7
   PubMed Web of Science ®Google Scholar
• Meininger D, Zalameda L, Liu Y, et al. Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim Biophys Acta 2011;1814:1947-54
   PubMed Web of Science ®Google Scholar
• Metz R, Duhadaway JB, Kamasani U, et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007;67:7082-7
   PubMed Web of Science ®Google Scholar
• Yuasa HJ, Ball HJ, Austin CJ, Hunt NH. 1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan. Comp Biochem Physiol B Biochem Mol Biol 2010;157:10-15
   Google Scholar
• Berthon C, Fontenay M, Corm S, et al. Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification. Leuk Res 2013;37:573-9
   PubMed Web of Science ®Google Scholar
• Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56
   PubMed Web of Science ®Google Scholar
• Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012;13:465-77
   PubMed Web of Science ®Google Scholar
• Stone TW, Darlington LG. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Br J Pharmacol 2013;169:1211-27
   PubMed Web of Science ®Google Scholar
• Stone TW, Stoy N, Darlington LG. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci 2013;34:136-43
   PubMed Web of Science ®Google Scholar
• Vecsei L, Szalardy L, Fulop F, Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 2013;12:64-82
   PubMed Web of Science ®Google Scholar
• Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 2006;6:613-25
   PubMed Web of Science ®Google Scholar
• Koblish HK, Hansbury MJ, Bowman KJ, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther 2010;9:489-98
   PubMed Web of Science ®Google Scholar
• Miller CL, Llenos IC, Dulay JR, et al. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 2004;15:618-29
   PubMed Web of Science ®Google Scholar
• Wu W, Nicolazzo JA, Wen L, et al. Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain. PLoS One 2013;8:e59749
   PubMed Web of Science ®Google Scholar
• Newlink Genetics. Imidazole derivatives as ido inhibitors. WO2012142237; 2012
   Google Scholar
• Ludwig Institute For Cancer Research Ltd. Ido inhibitors and therapeutic uses thereof. WO2011045340; 2011
   Google Scholar
• Ludwig Institute For Cancer Research Ltd. Ido inhibitors and therapeutic uses thereof. WO2011045341; 2011
   Google Scholar
• Dolusic E, Larrieu P, Blanc S, et al. Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors. Eur J Med Chem 2011;46:3058-65
   PubMed Web of Science ®Google Scholar
• Incyte Corp. N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase. WO2008036642; 2008
   Google Scholar
• Incyte Corp. Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase. WO2008036643; 2008
   Google Scholar
• Incyte Corp. Amidines as modulators of indoleamine 2,3-dioxygenase. WO2008036652; 2008
   Google Scholar
• Incyte Corp. N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase. WO2008036653; 2008
   Google Scholar